Computational modeling has become a crucial tool in drug design, offering efficiency and cost-effectiveness. This paper discusses the various computational modeling techniques used in drug design and their role in enabling efficient drug discovery strategies. Molecular docking predicts the binding affinity of a small molecule to a target protein, allowing the researchers to identify potential lead compounds and optimize their interactions. Molecular dynamics simulations provide insights into protein-ligand complexes, enabling the exploration of conformational changes, binding free energies, and fundamental protein-ligand interactions. Integrating computational modeling with machine learning algorithms, such as QSAR modeling and virtual screening, enables the prediction of compound properties and prioritizes potential drug candidates. High-performance computing resources and advanced algorithms are essential for accelerating drug design workflows, with parallel computing, cloud computing, and GPU acceleration reducing computational time. The paper also addresses the challenges and limitations of computational modeling in drug design, such as the accuracy of scoring functions, protein flexibility representation, and validation of predictive models. It emphasizes the need for experimental validation and iterative refinement of computational predictions to ensure the reliability and efficacy of designed drugs.
Objective:: The purpose of this study is to provide a thorough examination of methods for improving ocular medication penetration within controlled-release formulations, with an emphasis on their relevance to the treatment of eye disorders. Method:: Employing a methodical and rigorous methodology, this study provides an in-depth survey of current knowledge and research on the topic. Research on iontophoresis, prodrugs, pH modulation, penetration enhancers, hydrogels, inserts, nanomicelles, microemulsions, dendrimers, contact lenses, cationic emulsions, and targeted drug delivery are only some of the many topics covered in this study. Results:: Results summarise and synthesize prior research to give useful insights into the efficacy and potential of controlled-release formulations in increasing ocular medication delivery, providing a thorough review of current insights into these techniques. Discussion:: The discussion portion of the review critically assesses the guiding principles, advantages, and downsides of each technique, and it also investigates the consequences and prospects for this developing subject. Conclusion:: The study highlights the revolutionary potential of controlled-release formulations in the treatment of ocular illnesses, highlighting the importance of overcoming the obstacles associated with restricted pharmaceutical penetration into ocular tissues. This study concludes the present level of knowledge and paves the way for future improvements in the area of ocular medication administration, making it an essential resource for scientists and medical professionals working on the subject.
Artificial Intelligence (AI) is going to revolutionize the drug discovery process by far accelerating the development of new drugs and making the discovery process much more accurate and cheaper. This work carries out a thorough analysis of more than 50 recent works, investigating the issue of AI as an aid in drug discovery and diagnosis. The research methodology will include summarizing the existing sources of literature concerning the application of AI in drug development, specifically on the machine learning and deep learning methods applied in terms of analyzing large amounts of data, predicting the toxicity of a drug, and finding potential drug candidates. There are several main findings in the study, which include that AI can increase the efficiency of the drug development processes and that AI can pre-determine the safety and effectiveness of drug compounds. Nonetheless, AI does not have an ethical role to play in relation to drug development, especially in terms of using novel chemicals and drugs, which must be in the hands of human beings. The study ends with a listing of a number of future directions of study, including making AI more transparent, finding solutions to data privacy, and developing AI to be applicable in personalized medicine. Regulators, policymakers, and researchers should proactively involve themselves in ensuring that ethics are inculcated in drug discovery that is driven by artificial intelligence.